select a format

Single User License
USD 2000 INR 128860
Site License
USD 4000 INR 257720
Corporate User License
USD 6000 INR 386580

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Tardive Dyskinesia-Pipeline Review, H2 2015

Tardive Dyskinesia-Pipeline Review, H2 2015


  • Products Id :- GMDHC6918IDB
  • |
  • Pages: 56
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Tardive Dyskinesia-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Tardive Dyskinesia-Pipeline Review, H2 2015', provides an overview of the Tardive Dyskinesia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tardive Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tardive Dyskinesia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Tardive Dyskinesia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tardive Dyskinesia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tardive Dyskinesia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tardive Dyskinesia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tardive Dyskinesia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tardive Dyskinesia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Tardive Dyskinesia Overview 6

Therapeutics Development 7

Pipeline Products for Tardive Dyskinesia-Overview 7

Pipeline Products for Tardive Dyskinesia-Comparative Analysis 8

Tardive Dyskinesia-Therapeutics under Development by Companies 9

Tardive Dyskinesia-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Tardive Dyskinesia-Products under Development by Companies 13

Tardive Dyskinesia-Companies Involved in Therapeutics Development 14

Addex Therapeutics Ltd 14

Contera Pharma ApS 15

Neurocrine Biosciences, Inc. 16

Synchroneuron Inc. 17

Teva Pharmaceutical Industries Limited 18

Tardive Dyskinesia-Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 25

Drug Profiles 26

acamprosate calcium SR-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

dipraglurant IR-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Drugs for Tardive Dyskinesia-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

dutetrabenazine ER-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

valbenazine-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Tardive Dyskinesia-Recent Pipeline Updates 34

Tardive Dyskinesia-Dormant Projects 43

Tardive Dyskinesia-Product Development Milestones 44

Featured News & Press Releases 44

Jun 16, 2015: Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia 44

Feb 03, 2015: Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia 45

Oct 30, 2014: Auspex Pharmaceuticals Initiates Second Pivotal Clinical Trial for SD-809 in Tardive Dyskinesia 45

Oct 30, 2014: Neurocrine Biosciences Receives Breakthrough Therapy Designation for NBI-98854 in Tardive Dyskinesia 46

Oct 20, 2014: Neurocrine Announces Initiation Of Phase III Study For VMAT2 Inhibitor NBI-98854 47

Jul 17, 2014: Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial for SD-809 in Tardive Dyskinesia 47

Feb 24, 2014: Synchroneuron Announces First Patient Dosed in Phase 2 Tardive Dyskinesia Clinical Trial 48

Jan 09, 2014: Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 48

Jan 06, 2014: Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study 50

Sep 09, 2013: Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia 52

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

Number of Products under Development for Tardive Dyskinesia, H2 2015 7

Number of Products under Development for Tardive Dyskinesia-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Comparative Analysis by Late Stage Development, H2 2015 10

Comparative Analysis by Clinical Stage Development, H2 2015 11

Comparative Analysis by Early Stage Development, H2 2015 12

Products under Development by Companies, H2 2015 13

Tardive Dyskinesia-Pipeline by Addex Therapeutics Ltd, H2 2015 14

Tardive Dyskinesia-Pipeline by Contera Pharma ApS, H2 2015 15

Tardive Dyskinesia-Pipeline by Neurocrine Biosciences, Inc., H2 2015 16

Tardive Dyskinesia-Pipeline by Synchroneuron Inc., H2 2015 17

Tardive Dyskinesia-Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 18

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Stage and Target, H2 2015 21

Number of Products by Stage and Mechanism of Action, H2 2015 23

Number of Products by Stage and Route of Administration, H2 2015 24

Number of Products by Stage and Molecule Type, H2 2015 25

Tardive Dyskinesia Therapeutics-Recent Pipeline Updates, H2 2015 34

Tardive Dyskinesia-Dormant Projects, H2 2015 43

List of Figures

Number of Products under Development for Tardive Dyskinesia, H2 2015 7

Number of Products under Development for Tardive Dyskinesia-Comparative Analysis, H2 2015 8

Number of Products under Development by Companies, H2 2015 9

Assessment by Monotherapy Products, H2 2015 19

Number of Products by Top 10 Targets, H2 2015 20

Number of Products by Stage and Top 10 Targets, H2 2015 20

Number of Products by Top 10 Mechanism of Actions, H2 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24

Number of Products by Stage and Top 10 Molecule Types, H2 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Contera Pharma ApS

Neurocrine Biosciences, Inc.

Synchroneuron Inc.

Teva Pharmaceutical Industries Limited

Tardive Dyskinesia Therapeutic Products under Development, Key Players in Tardive Dyskinesia Therapeutics, Tardive Dyskinesia Pipeline Overview, Tardive Dyskinesia Pipeline, Tardive Dyskinesia Pipeline Assessment


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com